Pharma major Wockhardt said on Thursday that it had achieved a breakthrough in the development of Glargine, a new generation advanced insulin
"We are growing fast. We are planning to double the manpower to 4,000 from 2,000 at present. Within a very short period we increased the number of employees by 500 to reach 2000," Biocon Chairman and Managing Director Kiran Mazumdar Shaw said.
It is regrettable that the IB has tried to devalue the expertise available both within the concerned ministry and in the scientific community by its allegations. Governments and NGOs in many western nations have not been accused of being 'anti-national' when they put their foot down on questionable practices by cash rich agri-business companies, says Rashme Sehgal.
Pharma major Wockhardt is looking to acquire a German firm this year to strengthen its position in Europe and has set an overall sales target of Rs 100 crore (Rs 1 billion) from its biotech products for this year.
'Shanferon', a recombinant interferon is used for patients suffering from chronic myeloid leukemia, chronic viral hepatitis and other cancers, a company release said.\n\n\n\n
These women are building billion-dollar brands, calling the shots in the financial markets, and crisscrossing the globe to broker international agreements and provide aid, the magazine noted
India's largest biotech firm Biocon on Wednesday launched its "recombinant human insulin (r-DNA), Insugen
Biotech firm Biocon on Wednesday reported a net profit of Rs 198 crore (Rs 1.98 billion) during 2004-2005, an increase of 42 per cent over Rs 139 crore (Rs 1.39 billion) in the previous fiscal.
Suit alleges fraud by hiding significant deficiencies in CGMP regulations enforced by US health regulator.
On course to become India's first biotech company to be listed on a stock exchange, Bangalore-based Biocon Ltd on Thursday kicked off a roadshow for its initial public offering that opens on March 11.
It would be advisable to look to companies that reported attractive growth during the first quarter, says Mudar Patherya
Geeta Anand has shared it with the staff of the Wall Street Journal, for which she works.
Even as basic and cellular operators have been unable to reach an agreement on the contentious limited mobility services, the two sides have now approached Communications Minister Arun Shourie for continuing dialogue on issues such as spectrum.\n\n\n\n
The Indian pharmaceutical players have the potential to corner about 25 per cent of the generic market amounting to $3.75 billion by 2007-08 through leveraging their low cost and technology advantage, according to Rabo India Finance report.
Biotech major Biocon, which has projected sales turnover of Rs 700-750 crore (Rs 7-7.5 billion) this year, on Friday said it will launch recombinant human insulin in two weeks.
Aurobindo Pharma, Cadila Healthcare and Serum Institute are readying their vaccine candidates.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances